Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Investment analysts at Zacks Research increased their Q3 2026 earnings estimates for shares of Nektar Therapeutics in a note issued to investors on Thursday, September 3rd. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of ($2.45) for the quarter, up from [...]
Research Analysts Set Expectations for NKTR Q3 Earnings
